Squamous Cell Carcinoma of the Head and Neck
Conditions
Brief summary
OPHELIA (OPHELIA (OlaParib and durvalumab in HEad and neck squamous celL carcInomA) trial is a Greek, investigator-initiated, randomized open-label window-of-opportunity phase II study. Patients with operable histologically documented squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx will be randomized between combination with durvalumab and olaparib, cisplatin and olaparib, monotherapy with olaparib or no treatment, before starting standard treatment.
Detailed description
OPHELIA is a window-of-opportunity phase II study randomized between combination with durvalumab and olaparib, cisplatin and olaparib, monotherapy with olaparib or no treatment, before starting standard treatment. Although patients will be randomized between the 4 arms, no formal comparison between the 4 arms will be performed.Patients allocated to the olaparib monotherapy arm will serve as a proof-of-concept to interpret the mechanism of action of olaparib. Patients allocated in the no treatment group will be used as control. The primary endpoint will be the change in the tumour Ki-67 before and after treatment with the combination of olaparib + durvalumab or olaparib + cisplatin or olaparib monotherapy. Secondary endpoints will be early tumour response by RECIST criteria, pathologic complete response rate, tolerability to treatment and surgical complications rate, and optionally, metabolic response assessed by FDG-PET/CT scan. Translational correlates will be tested in tumour tissue, plasma and germline DNA. All the endpoints will be analyzed by an as treated analysis since the trial does not include a formal comparison of the treatment arms. Administration of olaparib monotherapy has been associated with reports of the following laboratory findings and/or clinical diagnoses, generally of mild or moderate severity (CTCAE Grade 1 or 2) and generally not requiring treatment discontinuation.
Interventions
DRUGOlaparib
50/25 mg BD split x 5 days
DRUGCisplatin
60 mg/m\^2 d1-d5
DRUGDurvalumab
1500 mg d1
Sponsors
AstraZeneca
Hellenic Cooperative Oncology Group
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Provision of signed written informed consent prior to any study specific procedures 2. Female and/or male patients aged 18 years and over 3. Body weight higher than 30 Kg 4. Newly diagnosed histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx 5. Provision of biological material (tumor tissue and blood), provision of signed informed consent for translational research 6. Patients selected for a primary surgical treatment 7. No prior anti-cancer treatment for head and neck cancer 8. Performance status ECOG 0-1 9. Adequate hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; haemoglobin ≥10g/dL 10. Adequate renal function: serum creatinine level 1.5 mg/dl and Glomelular Filtration Rate50 ml/min by Cockroft/Gault formula 11. Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alkaline phosphatase, AST (SGOT), ALT (SGPT) 5xULN 12. No active rheumatoid arthritis, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation. 13. Ability to swallow tablets. 14. Regular follow-up feasible 15. Baseline evaluations performed before registration: clinical and blood evaluations no more than 1 week (7 days) prior to registration, tumour assessment (CT or MRI scan of the head and neck, chest, abdomen and pelvis at the discretion of the investigator) no more than 30 days prior to registration 16. Treatment initiation planned less than 1 week (7 days) after registration 17. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: 1. Women \<50 years of age would be considered post-menopausal if theyhave been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). 2. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \>1 year ago, had chemotherapy-induced menopause with last menses \>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). For female patients of childbearing potential, negative serum pregnancy test within 1 week (7 days) prior of starting study treatment 18. Women of childbearing potential and their partners, who are sexually active, must agree to the use of TWO highly effective forms of contraception in combination, throughout the period of taking study treatment and for at least 1-6 month (according to the treatment group) after last dose of study drug(s) (where applicable). Male patients and their partners, who are sexually active and of childbearing potential, must agree to the use of TWO highly effective forms of contraception in combination, throughout the period of taking study treatment and for 3- 6 months (according tot he treatment group) after last dose of study drug(s) (where applicable).
Exclusion criteria
1. Metastatic or locally advanced unresectable disease 2. Uncontrolled hypercalcemia 3. Concomitant unplanned antitumour therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy) 4. Treatment with any other investigational medicinal product within 28 days prior to study entry 5. Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab 6. Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IMP and up to 30 days after the last dose of IMP. 7. Treatment with CYP3A4 inhibitors as well as inducers, unless discontinued 7 days prior to randomization 8. Any of the following within 3 months prior to inclusion: grade 3-4 gastrointestinal bleeding, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulitis 9. Other concomitant or previous malignancy, except: i) adequately treated in-situ carcinoma of the uterine cervix, ii) basal or squamous cell carcinoma of the skin, iii) cancer in complete remission for 5 years 10. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days 11. Pregnant or breastfeeding women 12. Patients with known allergy to any excipients to study drugs 13. History of myocardial infarction and/or stroke or other arterialthrombotic events or pulmonary embolism or unstable angina pectoris within 6 months prior to registration 14. No features suggestive of myelodysplastic syndrome/ acute myeloid leukemia MDS/ AML 15. Poorly controlled cardiac arrhythmias 16. Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, bowel obstruction or inability to take oral medication 17. Active rheumatoid arthritis, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation. 18. History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan 19. Other clinically significant disease or co-morbidity which may adversely affect the safe delivery of treatment within this trial 20. Known history of positive tests for human immunodeficiency virus (HIV) infection, hepatitis A or C virus, acute or chronic active hepatitis B infection 21. History of severe tumour bleeding or bleeding disorders 22. No blood transfusion within the 28 days prior to study 23. Poorly controlled anti-coagulation therapy (INR3.0 on coumadin or heparin compounds) 24. Palliative radiation therapy within 4 weeks prior to registration 25. Pregnancy or men or women of reproductive age not agreeing to use contraceptive measures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigation of the change in the tumour Ki-67 before and after treatment with the combination of olaparib + durvalumab or olaparib + cisplatin or olaparib monotherapy. | At baseline and at the day of the surgery or 2nd biopsy (at days 23-29 days) |
Secondary
| Measure | Time frame |
|---|---|
| Pathologic complete response rate | On week 4 only for operable patients |
| Metabolic response rate assessed by FDG-PET/CT scan (optional) | At baseline, on week 4 |
| Number of participants with tolerability to the treatment. | From the 1st day of therapy and every week for 4 weeks maximum and 90 days after last therapy administration |
| Surgical complication rate | Up to 30 days after surgery or the day of initiation of the next anticancer therapy |
| Mutations in genes associated with DNA repair | At baseline, on day of surgery or the 2nd biopsy (at days 23-29) |
| Expression of tissue biomarker: PARP1 | At baseline, on day of surgery or the 2nd biopsy (at days 23-29) |
| Expression of tissue biomarker: BRACA1,2 | At baseline, on day of surgery or the 2nd biopsy (at days 23-29) |
| Expression of tissue biomarker: ERCC1 | At baseline, on day of surgery or the 2nd biopsy (at days 23-29) |
| Expression of tissue biomarker: PDL-1 | At baseline, on day of surgery or the 2nd biopsy (at days 23-29) |
| Expression of tissue biomarker: TILs | At baseline, on day of surgery or the 2nd biopsy (at days 23-29) |
| Plasma methylation biomarker: PARP1 methylation in plasma cell-free DNA | At baseline, a day before surgery and 90 days after surgery |
| Objective response rate according to RECIST 1.1 criteria | Imaging studies will be performed at baseline and on week 4 |
| Plasma methylation biomarker: ERCC1 methylation in plasma cell-free DNA | At baseline, a day before surgery and 90 days after surgery |
| Plasma methylation biomarker: RAD51C methylation in plasma cell-free DNA | At baseline, a day before surgery and 90 days after surgery |
| Single-nucleotide polymorphisms: PARP-1 Val762Ala | Sample will be collected once at baseline |
| Single-nucleotide polymorphisms: ERCC1 Asn118Asn (C/T) | Sample will be collected once at baseline |
| Single-nucleotide polymorphisms:ERCC2 Lys751Gln (T/G) | Sample will be collected once at baseline |
| Single-nucleotide polymorphisms: GSTP1 Ile105Val (A/G) | Sample will be collected once at baseline |
| Single-nucleotide polymorphisms: XPD Lys751Gln (A/C, C/C) | Sample will be collected once at baseline |
| Single-nucleotide polymorphisms: XRCC1 Arg399Gln (G/A) | Sample will be collected once at baseline |
| Circulating tumor cells (CTCs) evaluated for DNA repair biomarkers | At baseline, a day before surgery and 90 days after surgery |
| Circulating tumor cells (CTCs) evaluated for PD-L1 | At baseline, a day before surgery and 90 days after surgery |
| Plasma methylation biomarker: BRCA1,2 methylation in plasma cell-free DNA | At baseline, a day before surgery and 90 days after surgery |
Countries
Greece
Outcome results
None listed